💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Yttrium Chloride

CHEMBL5316164 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
195.3 g/mol
LogP
—
Phase
4

Yttrium chloride is an inorganic yttrium salt that serves primarily as a precursor and starting material for the synthesis of radioactive yttrium-90 labeled radiopharmaceuticals used in radioimmunotherapy and targeted radionuclide therapy of lymphomas and other cancers. The stable yttrium chloride can be used in research applications and as a pharmaceutical intermediate. In oncology, yttrium chemistry underpins radiolabeled antibody conjugates used for lymphoma treatment.

分子量

195.2600 g/mol

TPSA

0.00 Ų

治疗领域

Lymphoma Leukemia

作用机制

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

SMILES

[Cl-].[Cl-].[Cl-].[Y+3]

InChI

InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3

Molecular Formula

Cl3Y

HBD / HBA

- / 3

可旋转键数

0

重原子数

4

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Yttrium chloride is an inorganic yttrium salt that serves primarily as a precursor and starting material for the synthesis of radioactive yttrium-90 labeled radiopharmaceuticals used in radioimmunotherapy and targeted radionuclide therapy of lymphomas and other cancers. The stable yttrium chloride can be used in research applications and as a pharmaceutical intermediate. In oncology, yttrium chemistry underpins radiolabeled antibody conjugates used for lymphoma treatment.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Yttrium Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5316164. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10198055. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.